Oral creatine vs placeboChange in pulmonary function · children with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 23 participantsLow
Oral olesoxime vs placeboChange in pulmonary function · non‐ambulatory children and adolescents with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 102 participantsLow
Oral gabapentin vs placeboChange in pulmonary function · adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 65 participantsLow
Oral hydroxyurea vs placeboChange in pulmonary function · children and adults with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 57 participantsLow
Oral valproic acid vs placeboChange in pulmonary function · ambulatory adults with SMA type III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted24 participantsLow
Oral phenylbutyrate vs placeboChange in pulmonary function · children with SMA type II1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 67 participantsLow
Oral valproic acid plus acetyl‐L‐carnitine vs placeboChange in pulmonary function · non‐ambulatory children with SMA types II and III1 finding from 1 reviewDrug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsLow